spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  IBS-D 

 HSMN NewsFeed - 19 Nov 2018
FDA Approves AEMCOLO(TM) (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 25 Apr 2018
FDA Grants Fast Track Designation for OrphoMed's ORP-101 for Treatment of IBS-D
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 23 Apr 2018
OrphoMed Appoints Gary M. Phillips, M.D. as President and Chief Executive Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 4 Jan 2018
OrphoMed Appoints Gastroenterology Expert and Industry Veteran Mark Sostek, M.D. as Chief Medical Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 13 Apr 2017
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 28 Mar 2017
Introducing PROMETHEUS(R) IBcause(TM): Convenient All-in-One Diagnostic Test for Persistent Diarrhea
Diagnostics Gastroenterology Product Launch
 HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 29 Feb 2016
Allergan Announces Receipt Of FDA Acceptable For Filing Letter For Generic XIFAXAN(R) ANDA
Biopharmaceuticals Generics Gastroenterology FDA
 HSMN NewsFeed - 21 Jan 2016
VIBERZI(TM) (eluxadoline) Phase III Trial Results Published in The New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 14 Dec 2015
Allergan Announces U.S. Availability of VIBERZI(TM) (eluxadoline) for Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults
Biopharmaceuticals Gastroenterology Product Launch
 HSMN NewsFeed - 17 Dec 2012
Lexicon's Drug Candidate For Irritable Bowel Syndrome Receives Fast Track Status From The FDA
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Mar 2011
Synergy Pharmaceuticals Appoints Dr. Laura Barrow as Vice President of Clinical Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Jan 2011
Furiex Receives FDA Fast Track Designation of MuDelta for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 15 May 2009
AGI Therapeutics: Top-line results of Phase III study of Rezular
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 27 May 2008
AMITIZA(R) (lubiprostone) 8 mcg Now Available to Treat Irritable Bowel Syndrome with Constipation in Adult Women
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Feb 2008
Apex Bioventures and Dynogen Pharmaceuticals Announce Definitive Merger Agreement
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jan 2008
Callisto Pharmaceuticals Announces Investor Conference Call to Provide Details on Guanilib Strategic Initiative in GI Disorders
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 Oct 2007
Callisto Pharmaceuticals Announces Major Strategic Initiative for Guanilib in GI Disorders
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Sep 2007
Microbia and Forest Laboratories Announce Linaclotide Co-Development and Co-Marketing Collaboration
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 May 2007
New Study Demonstrates That Lubiprostone May Improve Symptom Relief Rates in Adults With Irritable Bowel Syndrome With Constipation (IBS-C)
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
AMITIZA(TM) (lubiprostone) Phase III Constipation Trial Results Demonstrate Improvements in Symptoms of Irritable Bowel Syndrome With Constipation
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
Study Reveals Zelnorm(R) May Be a Safe and Effective Treatment for Additional Group of IBS Patients With a Mixed Bowel Pattern
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 May 2006
New Study Demonstrates That AMITIZA(TM) (lubiprostone) May Help Improve Symptoms of Irritable Bowel Syndrome With Constipation
Biopharmaceuticals Gastroenterology
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
IBS-D
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.